Search Medical Condition
Please enter condition
Please choose location from dropdown

Dublin 24, Ireland Clinical Trials

A listing of Dublin 24, Ireland clinical trials actively recruiting patients volunteers.

RESULTS

Found (212) clinical trials

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

The estimated total time on study for each participant is up to 55 months which consists of a screening period of up to 30 days, an open label treatment period of up to 48 months and a follow up period of up to 6-month after the last dose of fitusiran

Phase

4.51 miles

Learn More »

Surgery in Treating Patients With Neuroblastoma

OBJECTIVES: - Evaluate the safety and efficacy of surgical treatment alone for stage II neuroblastoma without N-myc amplification (NMA). - Describe predictive factors of relapse and survival for stages I and II neuroblastoma without NMA treated by surgery alone. OUTLINE: Patients with localized resectable tumors undergo surgery. Postoperative evaluations are ...

Phase

4.6 miles

Learn More »

Combination Chemotherapy With or Without Filgrastim Before Surgery High-Dose Chemotherapy and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

OBJECTIVES: - Compare the efficacy of myeloablative therapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan, in terms of 3- and 5-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), in patients with high-risk neuroblastoma. - Compare the 3-year EFS in these patients treated with isotretinoin with ...

Phase

4.6 miles

Learn More »

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

OBJECTIVES: - Investigate inter-individual variability in the pharmacokinetics of selected anticancer drugs in infants and children age < 2 years on current dosing schedules. - Compare drug exposures and degree of pharmacokinetic variability in children < 2 years with data obtained from published studies in older children. - Relate inter-individual ...

Phase N/A

4.6 miles

Learn More »

Pharmacokinetics of Dactinomycin in Young Patients With Cancer

OBJECTIVES: - Determine the pharmacokinetics (PKs) of dactinomycin in pediatric patients with cancer. - Determine the degree of interpatient variation in the PKs of this drug. - Determine the influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs in these patients. - Correlate drug PKs ...

Phase N/A

4.6 miles

Learn More »

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

OBJECTIVES: - Improve the outcome in pediatric patients with low-risk rhabdomyosarcoma (RMS) treated with vincristine and dactinomycin alone. - Evaluate whether the outcome for older patients with standard-risk RMS with favorable features may be improved/maintained by administering a treatment with limited intensity. - Evaluate whether chemotherapy intensity for patients with ...

Phase

4.6 miles

Learn More »

Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01

OBJECTIVES: - Determine the late effects of treatment and the quality-of-life of patients with germ cell tumors (GCT) previously treated on clinical trial CCLG-GC-1979-01 or CCLG-GC-1989-01. - Evaluate the late effects of carboplatin, etoposide, and bleomycin in patients treated on clinical trial CCLG-GC-1989-01. - Determine the toxicity of bleomycin and ...

Phase N/A

4.6 miles

Learn More »

CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

OBJECTIVES: Primary - To determine the CYP3A5 genotype in young patients with cancer who have received ifosfamide. - To document renal function and nephrotoxicity on one occasion between 1 month and 5 years after completion of ifosfamide treatment. - To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity. Secondary ...

Phase N/A

4.6 miles

Learn More »

Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma

OBJECTIVES: Primary - To evaluate the time to death in patients with newly diagnosed diffuse pontine gliomas, when treated with the combination of concomitant low-dose oral temozolomide and radiotherapy, followed by up to 12 months of maintenance therapy with extended low-dose temozolomide. - To assess the quality of life of ...

Phase

4.6 miles

Learn More »

Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

OBJECTIVES: Primary - Determine survival rates (event-free survival and overall survival [OS]) and the pattern of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery. - Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response ...

Phase

4.6 miles

Learn More »